High risk of thromboemboli early after bioprosthetic cardiac valve replacement
M Heras,
JH Chesebro,
V Fuster,
WJ Penny,
DE Grill,
KR Bailey,
GK Danielson,
TA Orszulak,
Pluth JR,
FJ Puga,
et al.
Division of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.
OBJECTIVES. We studied the rate of thromboembolism in patients undergoing bioprosthetic replacement of the aortic or mitral valve, or both, at serial intervals after operation and the effects of anticoagulant or antiplatelet treatment and risk factors. BACKGROUND. Thromboembolism appears to occur early after operation, but the incidence, timing and risk factors for thromboembolism and the role, timing, adequacy, effectiveness, duration and risk of anticoagulation and antiplatelet agents are uncertain. METHODS. The rate of thromboembolism was studied at three time intervals after operation (1 to 10, 11 to 90 and > 90 days) in 816 patients who underwent bioprosthetic replacement of the aortic or mitral valve, or both, at the Mayo Clinic from January 1975 to December 1982. The effect of antithrombotic therapy (warfarin, aspirin or dipyridamole, alone or in combination) was evaluated. RESULTS. Median follow-up of surviving patients was 8.6 years. The rate of thromboembolism (%/year) decreased significantly (p < 0.01) at each time interval after operation (1 to 10, 11 to 90 and > 90 days) for mitral valve replacement (55%, 10% and 2.4%/year, respectively) and over the first time interval for aortic valve replacement (41%, 3.6% and 1.9%/year, respectively). During the first 10 days, 52% to 70% of prothrombin time ratios were low (< 1.5 x control). Patients with mitral valve replacement who received anticoagulation had a lower rate of thromboembolism for the entire follow-up period (2.5%/year with vs. 3.9%/year without anticoagulation, p = 0.05). Of 112 patients with a first thromboembolic episode, permanent disability occurred in 38% and death in 4%. Risk factors for emboli were lack of anticoagulation, mitral valve location, history of thromboembolism and increasing age. Only 10% of aortic, 44% of mitral and 17% of double valve recipients had anticoagulation at the time of an event. Patients with bleeding episodes (2.3%/year) were older and usually underwent anticoagulation. Blood transfusions were required in 60 of 111 patients (1.2%/year), and 13 patients (0.3%/year) died. CONCLUSIONS. Thromboembolic risk was especially high for aortic and mitral valve replacement for 90 days after operation, and overall was increased with lack of anticoagulation, mitral valve location, previous thromboembolism and increasing age. Anticoagulation reduced thromboemboli and appears to be indicated in all patients as early as possible for 3 months and thereafter in those with risk factors, but needs prospective testing.
This article has been cited by other articles:
|
|
|
|
 
H. Imagawa, M. Ryugo, F. Shikata, T. Nakata, M. Nagashima, and K. Kawachi
Coagulant activity during one year after bioprosthetic aortic valve replacement
Interactive CardioVascular and Thoracic Surgery,
April 1, 2009;
8(4):
417 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Pibarot and J. G. Dumesnil
Prosthetic Heart Valves: Selection of the Optimal Prosthesis and Long-Term Management
Circulation,
February 24, 2009;
119(7):
1034 - 1048.
[Full Text]
[PDF]
|
|
|
|
|
|
|
2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al.
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation,
October 7, 2008;
118(15):
e523 - e661.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al.
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
e1 - e142.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit
Guideline on antiplatelet and anticoagulation management in cardiac surgery.
Eur. J. Cardiothorac. Surg.,
July 1, 2008;
34(1):
73 - 92.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Thompson, T. M. Sundt, M. E. Sarano, P. J. Santrach, and H. V. Schaff
In-Patient International Normalized Ratio Self-Testing Instruction After Mechanical Heart Valve Implantation
Ann. Thorac. Surg.,
June 1, 2008;
85(6):
2046 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker
Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
593S - 629S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Aramendi and C.-A. Mestres
Antithrombotic therapy after bioprosthetic aortic valve replacement
Eur. J. Cardiothorac. Surg.,
April 1, 2008;
33(4):
529 - 530.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colli, J.-P. Verhoye, R. Heijmen, J. T. Strauch, J. A.J. Hyde, D. Pagano, M. Antunes, H. Koertke, S. K. Ohri, D. H. L. Bail, et al.
Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results
Eur. J. Cardiothorac. Surg.,
April 1, 2008;
33(4):
531 - 536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Russo, F. Grigioni, J.-F. Avierinos, W. K. Freeman, R. Suri, H. Michelena, R. Brown, T. M. Sundt, and M. Enriquez-Sarano
Thromboembolic Complications After Surgical Correction of Mitral Regurgitation: Incidence, Predictors, and Clinical Implications
J. Am. Coll. Cardiol.,
March 25, 2008;
51(12):
1203 - 1211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gudbjartsson, T. Absi, and S. Aranki
Mitral Valve Replacement
Card. Surg. Adult,
January 1, 2008;
3(2008):
1031 - 1068.
[Full Text]
|
|
|
|
|
|
|
H. V. Schaff and R. M. Suri
Multiple Valve Disease
Card. Surg. Adult,
January 1, 2008;
3(2008):
1129 - 1158.
[Full Text]
|
|
|
|
|
|
|
M. Brueck, W. Kramer, P. Vogt, N. Steinert, P. Roth, G. Gorlach, M. Schonburg, and M. C. Heidt
Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors
Eur. J. Cardiothorac. Surg.,
July 1, 2007;
32(1):
108 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. di Marco, S. Grendene, G. Feltrin, D. Meneghetti, and G. Gerosa
Antiplatelet therapy in patients receiving aortic bioprostheses: A report of clinical and instrumental safety
J. Thorac. Cardiovasc. Surg.,
June 1, 2007;
133(6):
1597 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colli, J.-P. Verhoye, A. Leguerrier, and T. Gherli
Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue
Eur. J. Cardiothorac. Surg.,
April 1, 2007;
31(4):
573 - 577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Nowell, E. Wilton, H. Markus, and M. Jahangiri
Antithrombotic therapy following bioprosthetic aortic valve replacement
Eur. J. Cardiothorac. Surg.,
April 1, 2007;
31(4):
578 - 585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.R. E. Jamieson, S. D. Moffatt-Bruce, P. Skarsgard, M. A. Hadi, J. Ye, G. J. Fradet, J. G. Abel, M. T. Janusz, A. Cheung, and E. Germann
Early Antithrombotic Therapy for Aortic Valve Bioprostheses: Is There an Indication for Routine Use?
Ann. Thorac. Surg.,
February 1, 2007;
83(2):
549 - 557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Roudaut, K. Serri, and S. Lafitte
Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations
Heart,
January 1, 2007;
93(1):
137 - 142.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. El-Husseiny, K. Salhiyyah, S. G. Raja, and J. Dunning
Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement?
Interactive CardioVascular and Thoracic Surgery,
October 1, 2006;
5(5):
616 - 623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al.
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
August 1, 2006;
48(3):
e1 - e148.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al.
ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
August 1, 2006;
48(3):
598 - 675.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. di Marco, M. Giordan, and G. Gerosa
Early antithrombotic therapy after aortic valve replacement with tissue valves: When the practice diverges from the guidelines
J. Thorac. Cardiovasc. Surg.,
June 1, 2006;
131(6):
1223 - 1223.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Zimmermann, T. Roussiekan, J. Winter, M. Kurt, E. Gams, F. Wenzel, and T. Hohlfeld
Platelet inhibition by aspirin after aortic valve replacement
J. Thorac. Cardiovasc. Surg.,
June 1, 2006;
131(6):
1392 - 1393.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kulik, F. D. Rubens, P. S. Wells, C. Kearon, T. G. Mesana, J. van Berkom, and B.-K. Lam
Early Postoperative Anticoagulation After Mechanical Valve Replacement: A Systematic Review
Ann. Thorac. Surg.,
February 1, 2006;
81(2):
770 - 781.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Aramendi, C.-A. Mestres, J. Martinez-Leon, V. Campos, G. Munoz, and C. Navas
Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial
Eur. J. Cardiothorac. Surg.,
May 1, 2005;
27(5):
854 - 860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.M. Sundt, K.J. Zehr, J.A. Dearani, R.C. Daly, C.J. Mullany, C.G.A. McGregor, F.J. Puga, T.A. Orszulak, and H.V. Schaff
Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?
J. Thorac. Cardiovasc. Surg.,
May 1, 2005;
129(5):
1024 - 1031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker
Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
457S - 482S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Gherli, A. Colli, C. Fragnito, F. Nicolini, B. Borrello, S. Saccani, R. D'Amico, and C. Beghi
Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement: A Prospective Study
Circulation,
August 3, 2004;
110(5):
496 - 500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Schulman
Care of Patients Receiving Long-Term Anticoagulant Therapy
N. Engl. J. Med.,
August 14, 2003;
349(7):
675 - 683.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Aramendi, C. A. Mestres, V. Campos, J. Martinez-Leon, C. Pontes, G. Munoz, and J. C. Navas
Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (TRAC): rationale and design for a prospective, randomized, co-operative trial
Interactive CardioVascular and Thoracic Surgery,
June 1, 2003;
2(2):
170 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Desai and G. T. Christakis
Stented Mechanical/Bioprosthetic Aortic Valve Replacement
Card. Surg. Adult,
January 1, 2003;
2(2003):
825 - 856.
[Full Text]
|
|
|
|
|
|
|
T. Gudbjartsson, S. Aranki, and L. H. Cohn
Mechanical/Bioprosthetic Mitral Valve Replacement
Card. Surg. Adult,
January 1, 2003;
2(2003):
951 - 986.
[Full Text]
|
|
|
|
|
|
|
H. V. Schaff and D. H. Marsh
Multiple Valve Disease
Card. Surg. Adult,
January 1, 2003;
2(2003):
1017 - 1045.
[Full Text]
|
|
|
|
|
|
|
K. Schror
Combination of oral anticoagulant and platelet inhibitor drugs: focus on the pharmacological aspects of optimizing antithrombotic therapy in mechanical heart valve replacement
Eur. Heart J. Suppl.,
December 1, 2001;
3(suppl_Q):
Q54 - Q59.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G.G. Turpie
Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves
Chest,
January 1, 2001;
119
(2009):
220S - 227S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. E. Jamieson, E. Germann, G. J Fradet, S. V Lichtenstein, R. T Miyagishima, W. E. Jamieson, E. Germann, G. J Fradet, S. V Lichtenstein, and R. T Miyagishima
Bioprostheses and Mechanical Prostheses Predictors of Performance
Asian Cardiovasc Thorac Ann,
June 1, 2000;
8(2):
121 - 126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Weinschelbaum, P. Stutzbach, M. Oliva, J. Zaidman, A. Torino, and E. Gabe
MANUAL DEBRIDEMENT OF THE AORTIC VALVE IN ELDERLY PATIENTS WITH DEGENERATIVE AORTIC STENOSIS
J. Thorac. Cardiovasc. Surg.,
June 1, 1999;
117(6):
1157 - 1165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Chesebro and V. Fuster
Optimal Antithrombotic Therapy for Mechanical Prosthetic Heart Valves
Circulation,
November 1, 1996;
94(9):
2055 - 2056.
[Full Text]
|
|
|
|
|
|
|
W. Vongpatanasin, L. D. Hillis, and R. A. Lange
Prosthetic Heart Valves
N. Engl. J. Med.,
August 8, 1996;
335(6):
407 - 416.
[Full Text]
[PDF]
|
|
|
|
